Cargando…
Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
Background: Recalcitrant neovascular age-related macular degeneration (rnAMD) despite intensive intravitreal anti-neovascular endothelial growth factor (VEGF) treatment, can be handled by switching to another anti-VEGF agent. This first systematic review and meta-analysis presents long-term data aft...
Autores principales: | Hänsli, Christof, Schild, Christin, Pfister, Isabel, Garweg, Justus G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051743/ https://www.ncbi.nlm.nih.gov/pubmed/36983970 http://dx.doi.org/10.3390/life13030814 |
Ejemplares similares
-
Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021) -
Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review
por: Garweg, Justus G., et al.
Publicado: (2023) -
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023) -
Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair
por: Hänsli, Christof, et al.
Publicado: (2022) -
Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series
por: Garweg, Justus G., et al.
Publicado: (2021)